GSGT.F Stock Overview
A clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 4 more risks
GenSight Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.32 |
| 52 Week High | €0.52 |
| 52 Week Low | €0.32 |
| Beta | 2.33 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -47.54% |
| 33 Year Change | -95.26% |
| 5 Year Change | -77.93% |
| Change since IPO | -95.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| GSGT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 2.2% |
| 1Y | -47.5% | 16.2% | 31.7% |
Return vs Industry: GSGT.F underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: GSGT.F underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| GSGT.F volatility | |
|---|---|
| GSGT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GSGT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GSGT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Laurence Rodriguez | www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
| GSGT.F fundamental statistics | |
|---|---|
| Market cap | US$37.78m |
| Earnings (TTM) | -US$20.94m |
| Revenue (TTM) | US$2.06m |
18.4x
P/S Ratio-1.8x
P/E RatioIs GSGT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSGT.F income statement (TTM) | |
|---|---|
| Revenue | €1.98m |
| Cost of Revenue | €0 |
| Gross Profit | €1.98m |
| Other Expenses | €22.08m |
| Earnings | -€20.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 23, 2025
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,017.51% |
| Debt/Equity Ratio | -85.5% |
How did GSGT.F perform over the long term?
See historical performance and comparison